Sign inJoin waitlistJoin the waitlist

SW

Samuel Wilkinson

Physician · Spectrum Psychiatric Group PC

Credentials: · · ·

History

Spectrum Psychiatric Group PC
Present

2016–2017
Psychiatry
Yale-New Haven Hospital
2012–2016
Brigham Young University, Mechanical Engineering
Johns Hopkins Univ Sch of Med
2008–2012

Research

The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis
Systematic review or meta-analysis · American Journal of Psychiatry · 2018 · First of 10 authors · 525 citations
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD)
Molecular Psychiatry · 2020 · 323 citations
Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3
American Journal of Geriatric Psychiatry · 2020 · 264 citations

Gerard Sanacora
36 papers
RO
Robert Ostroff
14 papers
Sanjay Mathew
13 papers
James Murrough
10 papers
SN
Sina Nikayin
9 papers · 2 as a resident
DD
Deepak Dsouza
7 papers
RR
Robert Rosenheck
7 papers
Brandon Kitay
6 papers · 1 as a resident
ED
Ella Daly
6 papers
MB
Michael Bloch
6 papers
Rachel Katz
6 papers · 4 as a fellow
RR
Rajiv Radhakrishnan
6 papers · 4 as a resident

Grants

Examining Intensive Outpatient Programs as a Potential Mechanism to Reduce Suicide Risk During the Post-Hospitalization Period Among Medicaid Recipients
National Institute of Mental Health · R01
Contact PI · $2.6M · Yale University
2023–2028
A Feasibility Trial of Esketamine Plus Cognitive Behavioral Therapy for Patients with Major Depressive Disorder Who Are Hospitalized for Suicidal Ideation
National Institute of Mental Health · R01
Contact PI · $3.2M · Yale University
2020–2025
Impact of Cannabis Legalization on Prescription Drug Use and Health Outcomes in Connecticut
National Institute on Drug Abuse · R21
PI · $475.4K · Yale University
2023–2025
Association of Electroconvulsive Therapy with Health Outcomes in Older Adults with Co-Occurring Depression and Dementia
National Institute of Mental Health · R21
Contact PI · $682.2K · Yale University
2019–2022

Clinical trials

PCORI Comparative Effectiveness Study-Esketamine (Spravato) vs. Ketamine-Equivalence Study
Principal investigator · Recruiting · Phase 3
Yale University
2025–2030
The OBSERVE Protocol
Principal investigator · Recruiting
Yale University
2024–2029
Cognitive Behavioral Therapy Following Esketamine for Major Depression and Suicidal Ideation for Relapse Prevention
Principal investigator · Completed
Yale University
2021–2025
Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression
Principal investigator · Completed
Yale University
2017–2020